Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel® (Oral Paclitaxel) Compared to Taxol® (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic HER2 Negative Breast Cancer

NCT03315364 is registered in ClinicalTrials.gov with Daehwa Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03315364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03315364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel® (Oral Paclitaxel) Compared to Taxol® (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic HER2 Negative Breast Cancer
Lead sponsor
Daehwa Pharmaceutical Co., Ltd.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
December 18, 2017
Completion date
November 30, 2028
Enrollment
549 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic breast cancer